PMID- 37890606
OWN - NLM
STAT- MEDLINE
DCOM- 20231122
LR  - 20231122
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 960
DP  - 2023 Dec 5
TI  - Catalpol ameliorates LPS-induced inflammatory response by activating AMPK/mTOR 
      signaling pathway in rat intestinal epithelial cells.
PG  - 176125
LID - S0014-2999(23)00639-8 [pii]
LID - 10.1016/j.ejphar.2023.176125 [doi]
AB  - Intestinal inflammation is a common clinical intestinal disease. Catalpol, a 
      natural iridoid compound, has been shown to have anti-inflammatory, anti-oxidant 
      and anti-apoptotic functions, but the mechanism of its protection against 
      intestinal inflammation is still unclear. This study investigated the protective 
      effect and potential mechanism of catalpol on the lipopolysaccharide 
      (LPS)-induced inflammatory response of intestinal epithelial cell-6 (IEC-6). The 
      results showed that catalpol could inhibit LPS-induced inflammatory response by 
      dose-dependently reducing the release of inflammatory factors, such as tumor 
      necrosis (TNF)-alpha, interleukin (IL)-1beta and IL-6, and inhibiting the nuclear factor 
      kappa-B (NF-kappaB) signaling pathway. Catalpol ameliorated cellular oxidative stress 
      by reducing reactive oxygen species (ROS) and malondialdehyde (MDA) levels and 
      increasing superoxide dismutase (SOD) and glutathione peroxidase (GSH-PX) 
      expression. Meanwhile, catalpol also inhibited cell apoptosis, decreased the 
      expression of B-cell lymphoma 2 (Bcl-2) - associated X (Bax), caspase 3 and 
      caspase 9, and increased the expression of Bcl-2. This study found that catalpol 
      activates AMP-activated protein kinase (AMPK) signaling pathway and inhibit 
      mammalian target of rapamycin (mTOR) phosphorylationthe. In a further study, 
      after inhibiting AMPK with dorsomorphin, the anti-inflammatory effects of 
      catalpol were significantly reduced. Therefore, catalpol ameliorates LPS-induced 
      inflammatory response by activating AMPK/mTOR signaling pathway in IEC-6 cells.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Gao, Feng
AU  - Gao F
AD  - Key Laboratory of Animal Biotechnology of the Ministry of Agriculture and Rural 
      Affairs, College of Veterinary Medicine, Northwest A&F University, Yangling, 
      712100, China.
FAU - He, Qifu
AU  - He Q
AD  - Key Laboratory of Animal Biotechnology of the Ministry of Agriculture and Rural 
      Affairs, College of Veterinary Medicine, Northwest A&F University, Yangling, 
      712100, China.
FAU - Wu, Shenghui
AU  - Wu S
AD  - Key Laboratory of Animal Biotechnology of the Ministry of Agriculture and Rural 
      Affairs, College of Veterinary Medicine, Northwest A&F University, Yangling, 
      712100, China.
FAU - Zhang, Kang
AU  - Zhang K
AD  - Key Laboratory of Animal Biotechnology of the Ministry of Agriculture and Rural 
      Affairs, College of Veterinary Medicine, Northwest A&F University, Yangling, 
      712100, China.
FAU - Xu, Zhiming
AU  - Xu Z
AD  - Key Laboratory of Animal Biotechnology of the Ministry of Agriculture and Rural 
      Affairs, College of Veterinary Medicine, Northwest A&F University, Yangling, 
      712100, China.
FAU - Kang, Jian
AU  - Kang J
AD  - Key Laboratory of Animal Biotechnology of the Ministry of Agriculture and Rural 
      Affairs, College of Veterinary Medicine, Northwest A&F University, Yangling, 
      712100, China.
FAU - Quan, Fusheng
AU  - Quan F
AD  - Key Laboratory of Animal Biotechnology of the Ministry of Agriculture and Rural 
      Affairs, College of Veterinary Medicine, Northwest A&F University, Yangling, 
      712100, China. Electronic address: quanfusheng@nwsuaf.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20231026
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Lipopolysaccharides)
RN  - 2415-24-9 (catalpol)
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
RN  - 0 (NF-kappa B)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (Antioxidants)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Anti-Inflammatory Agents)
RN  - EC 2.7.1.1 (mTOR protein, rat)
SB  - IM
MH  - Rats
MH  - Animals
MH  - *Lipopolysaccharides/pharmacology
MH  - *AMP-Activated Protein Kinases/metabolism
MH  - Signal Transduction
MH  - NF-kappa B/metabolism
MH  - Epithelial Cells/metabolism
MH  - TOR Serine-Threonine Kinases/metabolism
MH  - Oxidative Stress
MH  - Tumor Necrosis Factor-alpha/metabolism
MH  - Antioxidants/pharmacology
MH  - Proto-Oncogene Proteins c-bcl-2/metabolism
MH  - Inflammation/chemically induced/drug therapy/prevention & control
MH  - Anti-Inflammatory Agents/pharmacology/therapeutic use
MH  - Mammals
OTO - NOTNLM
OT  - AMPK/mTOR signaling pathway
OT  - Apoptosis
OT  - Catalpol
OT  - Intestinal inflammation
OT  - Oxidative stress
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/10/28 11:42
MHDA- 2023/11/22 06:43
CRDT- 2023/10/27 19:28
PHST- 2023/02/23 00:00 [received]
PHST- 2023/10/01 00:00 [revised]
PHST- 2023/10/16 00:00 [accepted]
PHST- 2023/11/22 06:43 [medline]
PHST- 2023/10/28 11:42 [pubmed]
PHST- 2023/10/27 19:28 [entrez]
AID - S0014-2999(23)00639-8 [pii]
AID - 10.1016/j.ejphar.2023.176125 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2023 Dec 5;960:176125. doi: 10.1016/j.ejphar.2023.176125. Epub 
      2023 Oct 26.